Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Over $400 Million Raised by U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings in 2012, Reports Brinson Patrick

PR Newswire April 8, 2013

Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

Marketwired April 5, 2013

Emerging Growth Equities, Ltd. Initiates Coverage of Sarepta Therapeutics, Inc. (SRPT) With a BUY Rating and $38.00 Price Target

PR Newswire March 11, 2013

BioMarin Pharma, Amgen, Sarepta Therapeutics, Chelsea Therapeutics Intl., and Theravance Early Briefing and Review

PR Newswire March 7, 2013

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments

Marketwired March 7, 2013

Sarepta's Marburg Drug Shows High Survival Rates After Intramuscular Delivery in Non-Human Primates

Marketwired March 4, 2013

Sarepta Therapeutics to Present at Cowen & Company 33rd Annual Healthcare Conference

Marketwired February 21, 2013

Over 25 Companies to Present at Emerald Groundhog Day Investment Forum

Business Wire February 5, 2013

Sarepta Therapeutics to Present Company Overview at the Leerink Swann Global Healthcare Conference

Marketwired February 4, 2013

Statement From Sarepta Therapeutics on Stock Volatility

Marketwired January 30, 2013

Free Research Report on Oshkosh Corp., OCZ Technology Group Inc., LipoScience, Inc., Netflix, Inc. and Sarepta Therapeutics, Inc.

PR Newswire January 28, 2013

Sarepta Therapeutics to Present Company Overview at the 2013 31st Annual JP Morgan Healthcare Conference

Marketwired December 28, 2012

Sarepta Therapeutics Enters Into Clinical Trial Agreement With the National Institutes of Health for Further Development of Influenza Drug

Marketwired December 21, 2012